Proven Safety of a DES with an Abluminal Biodegradable Polymer

Biodegradable Polymer

Confirmed Safety

  • with a 12.3% reduction in MACE compared to the Sirolimus eluting stent at 12 months in LEADERS2
  • with no late or very late stent thrombosis in STEALTH I3 out to 4 years

Superior strut coverage at follow up

10 times better strut coverage4 of an abluminal biodegradable polymer BES than a durable symmetric polymer SES

  • Abluminal biodegradable polymer BES achieves 96.4% of near to complete strut coverage

Superior stent apposition

More than 20 times better stent apposition4 of an abluminal biodegradable polymer BES than a durable symmetric polymer SES

Biolimus A9™ eluting stent with abluminal biodegradable polymer demonstrates preserved vasomotion5

  • A high pacing stimulation induced abnormal vasomotion (vasoconstruction) of the Sirolimus eluting stented vessel when normal vasomotion (vasodilation) was observed in the Biolimus A9™ eluting stented vessel


    • CAUTION: Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

    Biosensors’ Interventional Cardiology products, including BioMatrix™, Gazelle™, S-Stent™ and Powerline™, are currently not available for sale in the United States.

    * Data on file - molecular weight <10kDa

    2.
    Serruys P.W., LEADERS: Taking the LEAD in DES Clinical Excellence - 12 months results, oral presentation, TCT 2008. Data applicable to the stent used in the LEADERS trial
    3.
    Grube E., Safety and Performance Evaluation of Biosensors Biolimus A9™ Eluting Stent (BioMatrix™) STEALTH I: a 4-year safety follow-up, e-poster, TCT 2008
    4.
    Di Mario C., OCT: Differences between biodegradable and durable polymers - Insights from the LEADERS trial, oral presentation, TCT 2008. Data applicable to the stent used in the LEADERS trial
    5.
    Hamilos M. et al. on behalf of the Nobori Core investigators, Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion, J Am Coll Cardiol 2008 51:2123-2129. Data applicable to the stent used in the Nobori Core trial